Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Motorola Solutions Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Motorola Solutions Inc trades at $470.61 (market cap $77.26B). The key difference: Motorola Solutions Inc is far larger — about 2.6× Alnylam Pharmaceuticals, Inc.'s market cap, and Motorola Solutions Inc pays a 1.04% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MSI | |
|---|---|---|
Market Cap | $29.60B | $77.26B |
Sector | Health | Technology |
52-Week High | $491.22 | $490.30 |
52-Week Low | $205.48 | $363.83 |
Enterprise Value | $27.56B | $86.17B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Motorola Solutions (MSI) trades at $468.70, up 1.45% on the day, reflecting strong momentum after Q2 2026 earnings beat estimates. The stock shows bullish technical signals with a golden cross pattern and is near its pivot point of $467. Fundamentally, revenue grew 13% year-over-year in Q2, with record backlog of $15.6 billion driving raised full-year guidance. Valuation ratios remain elevated with a P/E of 36.79, while profitability is robust with a net margin of 17.44% and ROE of 91.98%.
Outlook is positive given strong demand in public safety segments and upward earnings revisions, but risks include high valuation sensitivity and execution challenges. The consensus price target of $533.80 implies ~14% upside, supported by 71% analyst buy ratings. Investors should weigh growth prospects against premium multiples and monitor cash flow trends amid significant investing outflows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
